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Abstract: Human metapneumovirus (HMPV) is a major pediatric respiratory pathogen with currently
no specific treatment or licensed vaccine. Different strategies to prevent this infection have been
evaluated, including live-attenuated vaccines (LAV) based on SH and/or G protein deletions. This
approach showed promising outcomes but has not been evaluated further using different viral strains.
In that regard, we previously showed that different HMPV strains harbor distinct in vitro fusogenic
and in vivo pathogenic phenotypes, possibly influencing the selection of vaccine strains. In this
study, we investigated the putative contribution of the low conserved SH or G accessory proteins in
such strain-dependent phenotypes and generated recombinant wild type (WT) and SH- or G-deleted
viruses derived from two different patient-derived HMPV strains, A1/C-85473 and B2/CAN98-75.
The ∆SH and ∆G deletions led to different strain-specific phenotypes in both LLC-MK2 cell and
reconstituted human airway epithelium models. More interestingly, the ∆G-85473 and especially
∆SH-C-85473 recombinant viruses conferred significant protection against HMPV challenge and
induced immunogenicity against a heterologous strain. In conclusion, our results show that the viral
genetic backbone should be considered in the design of live-attenuated HMPV vaccines, and that a
SH-deleted virus based on the A1/C-85473 HMPV strain could be a promising LAV candidate as it is
both attenuated and protective in mice while being efficiently produced in a cell-based system.
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1. Introduction
Human metapneumovirus (HMPV) is a worldwide cause of acute respiratory tract infections
(ARTI) among children, the elderly and immunocompromised individuals [1,2]. HMPV infections
share many features with those of the human respiratory syncytial virus (HRSV), also belonging to the
Pneumoviridae family [3,4]. Despite the important clinical burden in infants and young children, no
licensed vaccine or specific and potent antiviral are currently available. While several HRSV vaccine
candidates have already entered clinical trials [5], some HMPV candidates have shown the potential
to progress towards clinical evaluation stages [6]. In that regard, different HMPV vaccine strategies
have been evaluated in animals, from formalin-inactivated vaccine, leading to enhanced disease [7], to
the elaboration of protein-based recombinant vaccines or live-attenuated vaccines (LAV) [6]. Among
them, LAV have shown the potential to elicit both humoral and mucosal immunity and mimic natural
viral replication routes, and they are therefore considered as highly suitable for HMPV pediatric
immunization strategies [8].
HMPV viruses are divided into two main phylogenetic lineages (A and B), which are further
divided into at least two sub-lineages (A1, A2a/A2b, B1 and B2) [9–13]. The HMPV genome is composed
of a negative single stranded RNA molecule of approximately 13 kb in length, containing eight genes
encoding for nine different proteins [14,15], including three surface glycoproteins (F, G, SH). The F
(fusion) glycoprotein is the major HMPV antigen [16] and leads to both attachment and fusion of
viral particles to the target cell [17]. In contrast, the exact role of G (glycoprotein) and SH (small
hydrophobic) glycoproteins is still a matter of debate. Indeed, the F protein of HMPV has been shown
to bind not only the cellular integrin αVβ1 receptor but also glycosaminoglycans (GAGs), such as
heparan sulfate, hence being able to substitute to the virus GAG-mediated attachment function once
exclusively attributed to the G protein [18–21]. Nonetheless, a role of the G protein was also suggested
in the host cell response to infection [22–24]. For instance, stimulation of the retinoid-acid inducible
gene 1 (RIG-I) signaling pathway was reported with a recombinant HMPV (rHMPV) lacking the G
protein (∆G) in vitro, which leads to increased NF-κB activation and enhanced cytokine secretion [22].
On the other hand, the SH protein has been shown to alter the NF-κB pathway [25] and also to form a
viroporin complex at the cell membrane [26].
The G and SH proteins have been considered for a long time as “accessory” non-essential proteins
for HMPV replication [27], as illustrated by recombinant HMPV viruses lacking either G, SH or both
genes that can replicate efficiently in vitro and in vivo [28]. Moreover, the contribution of G and SH
proteins to HMPV antigenicity, as well as the attenuation phenotype associated to G-deleted virus,
led to the consideration of such modified viruses as potential LAV candidates [16,27]. However,
the achievement of such perspectives is nuanced by the fact that all previous studies were based
on a unique HMPV backbone, notably the prototypical CAN97-83 strain from the A2 sub-lineage.
In that regard, many HMPV subtypes co-circulate each year with high genetic diversity among A
and B subtypes, particularly in the case of the less conserved G and SH proteins, with approximately
37% and 59% amino acid sequence homologies between subtypes, respectively [9,14]. In parallel,
we and others previously demonstrated that HMPV viruses diverge in their in vitro and/or in vivo
phenotypes in a strain-dependent manner, notably by considering the HMPV F and G proteins and
their functions [18,29–33].
In this context, we generated recombinant wild type (WT) and SH- or G-deleted viruses (∆SH
and ∆G respectively) from two patient-derived HMPV strains (A1/C-85473 and B2/CAN98-75) and
compared the respective functional impacts of SH and G deletions. In this context, we observed
different strain-specific phenotypes both in LLC-MK2 cells and reconstituted human airway epithelium
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(HAE) models that provided new insights on the importance of the genetic background in the design
of HMPV LAV. This prompted us to evaluate the ∆SH-C-85473 and ∆G-C-85473 recombinant viruses
in BALB/c mice for their capacity to induce efficiently neutralizing antibody response, recruit immune
cells in lungs and protect mice against lethal HMPV challenge. Our results suggest that an HMPV
C-85473 strain-based LAV harboring SH and/or G deletions would be a promising platform for further
development of pneumovirus vaccine candidates.
2. Materials and Methods
2.1. Cells
LLC-MK2 cells (ATCC CCL-7) were maintained in minimal essential medium (MEM, Life
Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Wisent) and
10 mM HEPES (Sigma-Aldrich, St. Louis, MO, USA). BSR-T7/5 cells (a kind gift from Dr Ursula
Buchholz at the National Institute of Allergy and Infectious Diseases in Bethesda, MD) were cultured in
MEM supplemented with 10% FBS, 1% non-essential amino acids (NEAA) (Life Technologies), 10 mM
HEPES (Sigma-Aldrich), 1% penicillin/streptomycin (Wisent) and 0.2 mg/mL geneticin (G418, Life
Technologies).
2.2. Rescue of Recombinant Viruses
pSP72 plasmids (Promega, Madison, WI, USA) encoding the full-length genomic cDNA of HMPV
B2/CAN98-75 or A1/C-85473 strains (GenBank accession numbers: AY145289.1 and KM408076.1,
respectively) were constructed as previously described [29,34]. To generate G- or SH-deleted viruses,
plasmids encoding HMPV antigenomes were amplified with Phusion DNA polymerase (New England
Biolabs, Ipswich, MA, USA) using primers (listed in Table 1) designed to match with the 3′ and 5′
regions of either G or SH genes, and taking care to conserve an intergenic sequence between flanking
genes (as represented in Figure 1A). After amplification, linear DNA was phosphorylated and re-ligated
by T4 Ligase. All plasmids were sequenced completely.
BSR-T7 cells were transfected with the HMPV antigenome constructions plus four supporting
plasmids, encoding N, P, L, and M2-1 ORFs of CAN98-75 and LLC-MK2 cells were added for co-culture
(two to three days), as previously described [29]. Cells were harvested, sonicated, centrifuged and
the supernatant was diluted to inoculate LLC-MK2 monolayers. After three to four amplification
passages onto LLC-MK2 cells, recombinant GFP-expressing viruses (rHMPV) were concentrated by
ultracentrifugation, resuspended in OptiMEM (Life Technologies) and stored at −80 ◦C. Viral stocks
were titrated as 50% tissue culture infectious doses (TCID50)/mL [35].
Table 1. List of primers.
Target Virus Background Forward Primer Reverse Primer
SH deletion
A1/C-85473 5′-GGGACAAGTAGTTATGGA-3′ 5′-ACTCTGATGTGTTTTTACTAAC-3′
B2/CAN98-75 5′-GGGACAAGTGGCCATG-3′ 5
′-ATTCTATTTATTTTTTACT
AACTTAAGTAAGCTT-3′
G deletion
A1/C-85473 5′-GAGACAAATAACAATGGATC-3′ 5′-ATATTATTGTTTTTACTTCTTAAATT-3′
B2/CAN98-75 5
′-GGGACAAATAACAATGGATCCG
TTTGTGAATCC-3′
5′-ATTTTCTTGTTTTGTA
TTACTCAGTGATTG-3′
N gene amplification A1/C-85473B2/CAN98-75
5′-AGAGTCTCAATACACAATAAA
AAGAGATGTAGG-3′
5′-CCTATCTCTGCAGCA
TATTTGTAATCAG-3′
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Figure 1. Construction of recombinant human metapneumovirus (HMPV) viruses and in vitro
replicative capacity of SH and G-deleted rHMPV viruses. (A) Schematic representation of the genome
of a recombinant GFP-expressing recombinant HMPV (rHMPV) viruses, with specific focus on the region
of the genome describing the position of primers used for the deletion strategy (arrow, Table 1). GS:
gene start. GE: gene end. IG: intergenic sequence. (B,C) LLC-MK2 monolayers in 24 wells-plates were
infected with each of the six recovered rHMPV strains (rCAN98-75, ∆SH-CAN98-75, ∆G-CAN98-75;
rC-85473, ∆SH-C-85473, ∆G-C-85473) at a MOI of 0.01. Supernatants were harvested every 24 h for
seven days, frozen, sonicated and titrated as tissue culture infectious doses (TCID50)/mL on LLC-MK2
cells. Growth curves represent mean titers of two independent experiments, with each time point
titrated in triplicate. ** p < 0.01, *** p < 0.001 when comparing each ∆SH/∆G virus to its wild type
(WT) counterpart using repeated measures two-way ANOVA. (D) Images of representative cytopathic
effects and spread of each virus at three days post-infection were captured using fluorescent microscopy
(10 ×magnification).
Vaccines 2019, 7, 164 5 of 17
2.3. In Vitro Experiments
For replication kinetics assays, confluent monolayers of LLC-MK2 cells in 24-wells plates were
infected with rHMPV viruses at a Multiplicity of Infection (MOI) of 0.01, as described previously [29].
Supernatants of infected wells were harvested in triplicate every 24 h for seven days and end-point
TCID50/mL titrations were performed on each sample.
For viral binding assays, confluent LLC-MK2 monolayers were washed with cold PBS and placed
on ice before rHMPV inoculation at MOI 0.5. After adsorption times on ice (30 min, 1, 2 or 3 h),
the inoculum was removed and replaced by fresh infection medium. After a 24 h incubation at 37 ◦C
and 5% CO2, cells were trypsinized, centrifuged and fixed using 2% formaldehyde. The percentages
of infected GFP positive cells over 1 × 104 total cells were measured by flow cytometry by using a
FACSCantoII analyzer (Becton Dickinson, Franklin lakes, NJ, USA) with FACSDiva software. Data
were analyzed by using the FlowJo software (Tree Star, Inc., Ashland, OR, USA) and normalized to
each virus inoculum.
For experimental virus entry assays, confluent LLC-MK2 cells were inoculated at a MOI of 0.5
after being placed on ice for 5 min and washed with cold PBS. The binding of virus to cells proceeded
for 2 h on ice until the inoculum was replaced by fresh infection medium. Cells were incubated
for 5 min, 30 min, 1 or 2 h at 37 ◦C and 5% CO2 to allow virus entry into cells, medium was then
removed and citrate buffer (40 mM sodium citrate dihydrate, 10 mM potassium chloride, 135 mM
sodium chloride, pH 3.0) was added to inactivate any remaining extracellular virus, as previously
described [36]. Cells were washed in PBS and incubated at 37 ◦C in fresh medium during 24 h. Infected
cells were quantified by GFP detection in flow cytometry and values were normalized to condition
without viral inactivation.
2.4. Infection of Reconstituted Human Airway Epithelium
In vitro 3D reconstituted human airway epithelium (HAE), derived from a pool of healthy donors’
primary bronchial cells (MucilAir™) were purchased from Epithelix (Genève, Switzerland). A viral
inoculum corresponding to a MOI of 0.1 was added onto HAE and incubated for 1.5 h at 37 ◦C and 5%
CO2. After five days of infection, captured images of infected HAE by fluorescent microscopy were
taken and the whole epithelium was scraped in RLT buffer (Qiagen, Hilden, Germany). Total RNA
was then extracted with RNeasy minikit (Qiagen) to perform viral genome quantification by RT-qPCR.
2.5. Real-Time (RT)-PCR
The total RNA extracted from samples was randomly reverse transcribed using SuperScriptII
RT (Invitrogen, Carlsbad, CA, USA) at 42 ◦C. Amplification of the HMPV N gene was performed by
quantitative PCR using SYBR Green qPCR Master Mix (Agilent, Santa Clara, CA, USA) and a set of
primers listed in Table 1. The calibration of HMPV N copies was assessed by amplification of a plasmid
kindly provided by Dr Ab Osterhaus (Erasmus Medical Center, Rotterdam, The Netherlands).
2.6. Animal Studies
Four- to six-week-old BALB/c mice (Charles River Laboratories, Wilmington, MA, USA), housed
in groups of five per micro-isolator cage, were infected intra-nasally with 5 × 105 TCID50 of rHMPV
C-85473 viruses (WT, ∆SH or ∆G). As a control group, mice were mock-infected intra-nasally with
OptiMEM. Animals were monitored on a daily basis during 14 days for weight loss, clinical signs,
reduced activity or ruﬄed fur and were sacrificed if they reached 20% of initial weight loss. Mice were
euthanized at 5 days post-infection (dpi) using sodium pentobarbital and lungs were removed for the
evaluation of viral titers or histopathological analysis, as described [29]. For virus titration, lungs were
homogenized in 1 mL of PBS before TCID50 titration or N quantification by RT-qPCR.
For HMPV challenge experiments three weeks post-immunization with 5 × 105 TCID50 of
recombinant rC-85473 viruses, mice were challenged intra-nasally with 1 × 106 TCID50 of WT rC-85473
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HMPV virus (50% lethal dose). Mice immunized with OptiMEM were used as negative control. Viral
titers and histopathological scores were evaluated at five days post-challenge as previously described.
Prior to immunization/infection and 21 days after challenge, blood samples were taken to evaluate the
neutralizing antibodies against the recombinant virus (rC-85473) or WT patient-derived homologous
C-85473 and heterologous CAN98-75 strains. Reciprocal neutralizing antibody titers were determined
by end-point dilution assay, as described [7].
To quantify pulmonary inflammatory cytokine/chemokine levels in HMPV-immunized challenged
mice, we euthanized mice and harvested lungs on days one and five post-challenge. Lungs were
homogenized in D-PBS containing protease inhibitors to perform the cytokines quantification using
a commercial multiplex mouse cytokine bead assay (Bio-Plex Pro Mouse Cytokine 23-plex Assay,
Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions. Results were analyzed
with the Luminex system (QIAGEN).
In order to analyze lung-infiltrating immune cells, mice were deeply anesthetized and perfused
intracardially with D-PBS without Ca2+ and Mg2+ on days one and five post-challenge. Lungs were
collected, digested with Liberase TL and processed to recover living leukocytes, as described [34]. Then,
cells were incubated on ice for 40 min with a pool of antibodies (anti-CD45, anti-Ly6G, anti-CD11b,
anti-CD170/Siglec-F, anti-Ly6C, anti-CD11c, anti-F4/80, anti-B220, anti-CD3ε, anti-CD4 and anti-CD8a,
purchased from BD) to discriminate cell populations. The count numbers of total pulmonary leukocytes
(CD45+), neutrophils (LyG6+), macrophages (SiglecF+, F4/80+), lymphocytes T (CD3ε+) CD4+, CD8+
and lymphocytes B (B220+) were measured by flow cytometry from whole living cells. Number of cells
were determined with Precision Count Beads™ (BioLegend, San Diego, CA, USA). Data acquisition
and analyses were performed by a BD LSRII flow cytometer and the BD FACSDiva software.
Animal studies were approved by the SFR Biosciences Ethics Committee (CECCAPP C015
Rhône-Alpes, protocol ENS_2017_019) according to European ethical guidelines 2010/63/UE on animal
experimentation and by the Animal Protection Committee of the Quebec University Health Centre
(Protocol CPAC 2017-140-2) according to Canadian Council guidelines on Animal Care.
2.7. Statistical Analysis
Two-way ANOVAs with Dunnett post-tests were used to compare data of ∆SH and ∆G HMPV to
their corresponding WT virus. Statistical analyses were performed using GraphPad Prism7.
3. Results
3.1. In Vitro Characteristics of ∆G- and ∆SH-HMPV Recombinant Viruses Differ Depending on the Viral
Strain Background
Based on our previous studies [29,30], we successfully generated by reverse genetics different
GFP-expressing HMPV recombinant viruses derived from the A1/C-85473 strain (rC-85473, ∆G-C-85473,
∆SH-C-85473) and the B2/CAN98-75 strain (rCAN98-75, ∆G-CAN98-75 and ∆SH-CAN98-75)
(Figure 1A). Rescued recombinant viruses were firstly assessed for their replicative capacity in
LLC-MK2 cells over a seven-day period (Figure 1B,C). While rCAN98-75 virus peaked at 8.95 × 105
TCID50/mL at 4 dpi, ∆SH-CAN98-75 virus showed reduced replication as early as 2 dpi, with a 24 h
delay to reach peak titer (1.95 × 105 TCID50/mL) (Figure 1B). A significantly more attenuated phenotype
was observed with the ∆G-CAN98-75 virus, for which the highest viral titer measured (5.72 × 104
TCID50/ml at 7 dpi) was delayed and 1.2 log10 lower than that of the WT (Figure 1B). This differential
replication among the three CAN98-75-based recombinant viruses was also illustrated by representative
fluorescent microscopy images of infected LLC-MK2 cells at 3 dpi, notably considering the extent of
viral spread and GFP positive cells (Figure 1D). On the contrary, no such important differences in
replication properties were observed between the two deleted C-85473-derived recombinant viruses
and their WT counterpart (Figure 1C). Peak viral titers of approximately 1 × 105 TCID50/mL for both the
C-85473-WT and∆SH-C-85473 viruses, or a peak of 4.22× 104 TCID50/mL for the∆G-C-85473 virus were
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reached by 4 dpi (Figure 1C). According to previous studies with the viral C-85473 background [29,30],
fluorescence microscopy showed that ∆SH-C-85473 and ∆G-C-85473 viruses harbored high viral spread
and hyperfusogenic phenotypes, comparable to the WT rC-85473 (Figure 1D).
Considering the different phenotypes of rHMPV virus derived from the A1/C-85473 and
B2/CAN98-75 strains and the “attachment” role attributed to the G protein, we further evaluated the
specific impact of the G and SH gene deletions on the binding and the entry of the rHMPV to LLC-MK2
cells (Figure 2). While the rCAN98-75 virus showed progressive binding kinetics, reaching a maximum
of 68% GFP-positive cells after 3 h of adsorption, the ∆SH-CAN98-75 virus showed faster binding in
the first hour, yet achieving a maximal plateau of 47% by 2 h (Figure 2A). Not surprisingly, the deletion
of the G protein significantly hampered the binding capacity of the ∆G-CAN98-75 virus, with a mean
of ~10% GFP-positive cells all throughout the experiment (Figure 2A). In contrast, and as observed
for the replicative capacities, the binding ability of the C-85473-derived viruses was not significantly
hampered at 3 h by the gene deletions: 57% for ∆SH- and 54% for ∆G-C-85473 versus 43% for the WT
rC-85473 (Figure 2B).
Figure 2. Binding and entry kinetics of WT, ∆SH- or ∆G- rHMPV viruses in LLC-MK2 cells. Binding
kinetics of (A) rCAN98-75-derived viruses and (B) rC-85473-derived viruses or entry kinetics of (C)
rCAN98-75-derived viruses and (D) rC-85473-derived viruses in LLC-MK2 cells were measured by
flow cytometry as described in Materials and Methods. Mean values represented triplicates in two
independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 when comparing each ∆SH / ∆G virus to
its WT counterpart using repeated measures two-way ANOVA.
Regarding cell entry kinetics, the ∆SH-CAN98-75 virus seemed to enter LLC-MK2 cells slower
than its WT counterpart and the ∆G-CAN98-75 virus, with 24% of ∆SH-CAN98-75-infected cells
after 120 min compared to 43% for WT and ∆G-CAN98-75 viruses (Figure 2C). Conversely, the three
rC-85473-derived viruses showed rather rapid cell entry kinetics with more than 36% of infected
cells after 60 min. Interestingly, both ∆SH- and ∆G-C-85473 viruses showed higher entry properties
compared to their WT counterpart after 120 min with 66%, 79% and 57% of infected cells, respectively
(Figure 2D).
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Altogether, our in vitro results on virus replication, cell binding and entry kinetics, suggested
that G and SH deletions had strong differential impact on HMPV phenotypes depending on the viral
background, hence highlighting a strain-dependent role of the viral surface proteins.
3.2. ∆G- and ∆SH-Viruses Harbor Different Replicative Properties in Reconstituted Human Airway
Epithelium
We further investigated the properties of ∆G- and ∆SH-viruses by using reconstituted human
airway epithelium (HAE) as a more physiological model of respiratory infection. Indeed, we previously
showed that this model is permissive to HMPV infection and globally mimics the in vivo host
respiratory epithelium response to such infection [37]. In line with these results, we observed that both
rCAN98-75 and rC-85473-derived viruses are also able to infect, replicate and spread within the HAE
(Figure 3).
Figure 3. Recombinant HMPV viruses differed in infectivity and viral growth in reconstituted human
airway epithelium (HAE). MucilAir™ epithelium from healthy donors were infected with the different
rHMPV strains at a MOI of 0.1. At 5 dpi, the viral spread in infected ciliated cells was monitored by
fluorescence microscopy (images at 10×magnification) and the quantity of viral genome was measured
by specific RT-qPCR against the N viral gene from epithelium lysates, respectively (A) and (B) for
rCAN98-75-derived viruses or (C) and (D) for rC-85473-derived viruses. Genome quantifications are
shown as means ± SD and represent experimental triplicates. ** p < 0.01, *** p < 0.001 when comparing
each ∆SH / ∆G virus to its WT counterpart using repeated measures two-way ANOVA.
Based on the GFP expression pattern within the infected HAE at 5 dpi, we observed that the
∆SH-CAN98-75 spread more efficiently than its WT counterpart, at the difference of the ∆G-CAN98-75
virus, which appeared dramatically impaired (Figure 3A). These results were confirmed by the
quantification of N gene copies number within the infected epithelium. In line with the fluorescent
microscopy observations, the viral quantifications at 5 dpi indicated a significant six-fold higher viral
replication of the ∆SH-CAN98-75 virus and 3.3 log10 lower values for the ∆G-CAN98-75 virus in
comparison to the WT CAN98-75 virus (Figure 3B). At the difference, the ∆SH-C-85473 virus acted
similarly to its WT counterpart, considering both spread pattern and viral replication within the HAE
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model (Figure 3C,D). In addition, the spread of the ∆G-C-85473 virus seemed to be more affected in
HAE model than in LLC-MK2 monolayer (Figure 3C) even though its replication diminished slightly
in comparison to the WT rC-85473 virus, considering the 30-fold decrease of the number of N gene
copies (Figure 3D).
These results indicate that rHMPV harbored different strain-dependent replicative properties in the
HAE model (Figure 3) compared to the LLC-MK2 model (Figure 1). In the CAN98-75 viral background,
the SH deletion significantly enhanced the viral replication and spread in HAE, whereas it caused a
deleterious delay of replication in LLC-MK2 cells. In addition, the G deletion appeared to attenuate
excessively the viral replication in HAE, in line with results in LLC-MK2 model. In contrast, rC-85473
viruses showed similar characteristics in both HAE and LLC-MK2 models, including comparable
replication phenotypes between the WT virus and its derived deleted viruses, and especially the
∆SH-C-85473 virus.
Altogether, considering the characteristics of the rC-85473-derived viruses in LLC-MK2 and HAE
models, we focused on this viral backbone to further investigate in vivo functional impact of SH- and
G-deletions and evaluate their potential in the development of LAV candidates.
3.3. Immunization with Deleted-C-85473 Viruses Reduces HMPV Disease Severity in Challenged BALB/c Mice
We therefore infected mice intra-nasally with 5 × 105 TCID50 of either ∆G-C-85473 or ∆SH-C-85473
viruses, the equivalent non-lethal dose inoculum needed to induce a significant (>10%) weight loss
with the WT rC-85473 virus at 7 dpi (Figure 4A). Similar to the mock (non-infected) group and in
contrast with the WT rC-85473, neither weight loss nor clinical signs were observed in the ∆G-C-85473
and ∆SH-C-85473-infected groups during the 14-day follow-up. In contrast, lung viral titers at 5 dpi
were comparable between WT and deleted viruses, as determined by both cell culture and molecular
methods (Figure 4B,C). In agreement with the weight curves, lower histopathological scores were
recorded for both ∆G-C-85473 and ∆SH-C-85473-infected mice compared to the WT group (1.8 and 2.4
versus 5.3, respectively), particularly owing to significant reductions in interstitial, perivascular and/or
intra-alveolar inflammation (Figure 4D).
We then evaluated the capacity of ∆SH- and ∆G-C-85473 attenuated viruses to protect mice from
a lethal viral challenge. Upon viral challenge with 1 × 106 TCID50 of rC-85473 virus, mock-immunized
mice showed significant (50%) HMPV-associated mortality, starting on day five post-challenge and
spanning until day eight post-challenge, with mean weight loss of 11% (peak after seven days)
(Figure 5A). Conversely, both ∆SH- and ∆G-C-85473-immunized mice groups, as well as control
rC-85473-immunized mice, were completely protected from HMPV-associated mortality induced by
viral challenge and showed mean maximum weight losses of 3%–4% of their initial weight (peak at
day two post-challenge) (Figure 5A,B).
Similarly, to the rC-85473 WT virus, the protection induced by immunization with ∆G-C-85473
and ∆SH-C-85473 was associated with the induction of high neutralizing antibody titers at 21 days
after challenge, particularly in the case of ∆SH-C-85473 (Table 2). Importantly, neutralization assays
also showed that induced antibody responses were effective in neutralizing WT patient-derived strains
as well as the heterologous CAN98-75 HMPV B strain (Table 2). In line with these results, we were
unable to recover HMPV viruses or detect viral genome from the lungs of any of the three different
rHMPV-immunized groups on day five post-challenge (Table 2). However, we still recorded reduced
but significant pulmonary inflammation in WT- and ∆G-C-85473-immunized mice, compared to
mock-immunized mice (scores of 7.5 and 7 versus 9.5, respectively), whereas ∆SH-C-85473-immunized
mice had a much lower histopathological score of 2.5 (Figure 5C). Indeed, ∆SH-C-85473-immunized
group showed reduced interstitial and perivascular inflammations and no bronchial and intra-alveolar
inflammation (Figure 5C). In contrast to mock-immunized mice, none of the rHMPV-immunized
groups developed pulmonary edema after viral challenge (Figure S1).
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Figure 4. Weight loss, lung viral titers and histopathological scores of BALB/c mice infected with
rC-85473-derived live-attenuated vaccines (LAV) candidates. BALB/c mice were intranasally infected
with 5 × 105 TCID50 of rC-85473 rHMPV viruses (WT, ∆SH and ∆G). (A) Weight loss was monitored
during 14 days since infection (n = 16). At 5 dpi, mice were euthanized and lungs were harvested to
measure viral titers by both TCID50 titration (B) and quantitative RT-PCR (C) (n = 4). (D) Cumulative
histopathological scores (bronchial, peribronchial, perivascular, interstitial, pleural and intra-alveolar
inflammation scores) of other infected mouse lungs were evaluated at 5 dpi (n = 5). Data are shown
as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 when comparing each ∆SH/∆G virus to its WT
counterpart using repeated measures two-way ANOVA.
Table 2. Immunogenicity and protective efficiency of HMPV C-85473-derived viruses in mice.
Imm. virus Imm. Inoculum
(log10 TCID50)
Reciprocal Neutralization Titer 21 Days
Post-Challenge against Different HMPV
Strains (n = 4) 1
Challenge Virus Replication in
Lungs Five Days Post-Challenge
(n = 4)
rC-85473 WT C-85473 WTCAN98-75
Mice with
Detectable
Virus (%)
Mean Virus Titer
(log10 N
copies/µg RNA)
mock 10 7.5 12.5 100 4.8 ± 4.3
rC-85473 5.7 >160 80 60 0 <1
∆SH-C-85473 5.7 >160 >160 >160 0 <1
∆G-C-85473 5.7 >160 80 70 0 <1
1 Sera were tested for neutralization efficiency against rC-85473 virus, which was the same recombinant virus used
for infectious challenge; WT C-85473, as homologous A1 virus; and WT CAN98-75, as heterologous B2 strain. Two
biological replicates per group were tested. The “naïve” status of mice was confirmed by neutralizing antibody
dosage of sera harvested one day before intranasal immunization (reciprocal titer <5). Imm. = immunization.
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Figure 5. Weight loss, survival and histopathological scores of HMPV-immunized mice after
viral challenge. BALB/c mice were intranasally immunized with 5 × 105 TCID50 of ∆SH-C-85473,
∆G-C-85473 or WT rC85473 viruses (immunization control), as previously described. Three weeks
after immunization, animals (n = 16) were inoculated with 1 × 106 TCID50 (LD50) of rC-85473 (viral
challenge). (A) Weight loss and (B) mortality were monitored during 14 days after the viral challenge
(n = 10). (C) Cumulative histopathological scores (bronchial, peribronchial, perivascular, interstitial,
pleural and intra-alveolar inflammation scores) of infected mouse lungs were evaluated on day five
post challenge (n = 2) while pulmonary viral titers were measured by RT-qPCR (n = 4, Table 2). Data
are shown as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 when comparing each ∆SH/∆G virus to
its WT counterpart using repeated measures two-way ANOVA.
To further characterize the immune response after viral challenge of the rHMPV-immunized mice,
we characterized the production of pulmonary cytokines/chemokines and the subsequent infiltration
of different immune cell populations into the lungs. As soon as one day after the challenge, we
measured high expression levels of cytokines, corresponding to an acute response to high dose of viral
challenge, as it is the case for RANTES (19,000 pg/mL, Figure 6A). Interestingly, higher levels of several
cytokines/chemokines (IL-10, IL-6, G-CSF, TNF-α) were measured in the lungs of ∆SH-immunized
mice in comparison with WT and ∆G-immunized groups (Figure 6A). In accordance with the absence
of detectable virus (Table 2) and the decreased histopathological scores (Figure 5C), the level of most
of the measured cytokines lowered five days post-challenge (Figure 6A). In addition, we observed
an important recruitment of leukocyte populations in rHMPV-immunized groups from day one after
challenge, which persisted for at least five days later (Figure 6B). Of note, the ∆SH-immunized group
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showed significant enhanced infiltration of leukocytes in lungs five days post-challenge, particularly T
CD4+, T CD8+ and B cell populations (Figure 6B).
Figure 6. HMPV-immunized mice showed distinct cytokine/chemokine and immune cell infiltration
profiles through time after viral challenge. BALB/c mice were intranasally immunized with 5
× 105 TCID50 of ∆SH-C-85473, ∆G-C-85473 or WT rC85473 viruses (immunization control), as
previously described. Three weeks after immunization, animals were inoculated with 1 × 106
TCID50 (LD50) of rC-85473 (viral challenge). (A) Pulmonary inflammatory cytokine/chemokine levels
in HMPV-immunized challenged mice were determined from lung homogenates on days one and
five post-challenge, using a multiplex bead-based assay. Six cytokines/chemokines (IFN-γ, IL-10,
IL-6, RANTES, G-CSF, TNF-α) were selected considering both their detection levels and significance
in HMPV-related disease. (B) Immune cell infiltration in lung homogenates was evaluated by flow
cytometry on days one and five post challenge. * p < 0.05; ** p < 0.01; *** p < 0.001 comparing each
group using repeated measures two-way ANOVA.
Overall, our results suggested that deleted rC-85473 viruses harbored distinct but attenuated
and protective properties in the BALB/c model against a lethal HMPV viral challenge, together with
reduced disease severity, weaker inflammatory responses and a balanced stimulation of the immune
response, especially in the case of the ∆SH-C-85473 virus.
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4. Discussion
Despite the necessity to develop vaccination strategies to prevent ARTI, neither FDA-approved
vaccine nor specific antiviral against HMPV are currently available [38,39]. Considering the major
burden of this virus in infants and young children, HMPV live-attenuated vaccines offer interesting
properties to protect this specific population [8]. In that regard, while the first and only phase I clinical
trial based on human-to-avian HMPV P substitution was non-conclusive [40], attenuation approaches
based on gene deletion showed promising results in animals [27,41]. Nevertheless, previous studies
on HMPV LAV were mainly restricted to the A2/CAN97-83 strain and did not take into account
the genetic variability of HMPV viruses between and within subgroups, especially regarding the
poorly conserved G and SH glycoproteins [42,43]. In fact, the limited knowledge on HMPV virulence
factors and their putative roles still hampers the development of efficient therapeutic and prophylactic
strategies against severe HMPV disease. In this study, we sought to address the problem of the impact
of viral background on the differential effect of G and SH deletions by using two patient-derived HMPV
strains, A1/C-85473 and B2/CAN98-75. We demonstrated that G- or SH-deleted A1/C-85473 viruses
had unchanged replicative capacity in vitro compared to their WT counterpart (Figure 1), in line with a
previous study advocating the putative “accessory role” of these two gene-products [27]. However, we
observed that viral replication in LLC-MK2 cells was significantly decreased when G and, to a lesser
extent SH, were deleted from the B2/CAN98-75 virus (Figure 1). Such a distinct replication phenotype
between A and B viruses (A1/C-85473 and A2/CAN97-83 vs. B2/CAN98-75) suggests that the HMPV
genetic background might influence the impact of gene deletions on viral fitness. This is of particular
importance if we consider efficient production yield (i.e., comparable to that of the WT virus) as a
major requirement for the development of a LAV candidate.
We also previously showed that C-85473 and CAN98-75 strains induce very different fusogenic
phenotypes in vitro and pathogenicity in vivo, thanks to the specific characteristics of their respective
F glycoproteins [29,30]. Besides its major role in viral fusion, the F protein may also retain importance
for viral binding and entry into cell [17,20,21]. In this way, the C-85473 virus appeared to be less
dependent on the G protein to perform virus-to-cell binding than the CAN98-75 virus (Figure 2).
It seems therefore possible that the lack of the G protein could be compensated by the hyperfusogenic
activity of the C-85473 F protein. In our study, the differential profiles exhibited by the two strains
strengthen this hypothesis, as illustrated by the enhanced entry kinetics of the rC-85473 virus in
comparison to the rCAN98-75 virus, despite the improved capacity of the latter to bind LLC-MK2
cells (Figure 2). Alternatively, although its specific function is still debated, SH is presumed to be a
putative cofactor of some F proteins and therefore it could participate in the viral entry [26]. In this
way, SH deletion could lead to mild viral attenuation in vitro, as reported for the ∆SH-CAN98-75 virus
in Figure 1.
Contrasting with the LLC-MK2 model, the replication and spread of both ∆G viruses was more
limited in the HAE model, whereas the ∆SH viruses showed efficient infectivity, notably in the case
of the ∆SH-CAN98-75 virus (Figure 3). Such divergent phenotypes between deleted viruses was
previously shown with HRSV, for which the G protein differently contributes to virus-cell binding
depending on both the cell lines and the virus strains studied [36]. In light of our results, we therefore
propose that the stratified nature and surface receptor configuration of the physiological HAE model,
combined with the presence of cilia and mucus, lead to a more limiting environment for effective
infection with a G-deleted HMPV virus. Taken together, our data show for the first time the importance
of HMPV background and experimental models which must be considered in the study of G and SH
protein functions.
Based on their specific characteristics in the LLC-MK2 and HAE models, we focused on the two
deleted (∆SH and ∆G) viruses issued from the C-85473 strain for further investigation in BALB/c
mice. At the difference of other small animal models previously used, the murine model allows the
monitoring of weight loss, lung viral replication/inflammation and other clinical signs during the time
course of HMPV infection [44]. In our study, the ∆SH-C-85473 and ∆G-C-85473 viruses replicated
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in mice lungs similarly to their WT counterpart at 5 dpi while inducing no weight loss or mortality
and lesser tissue inflammation (Figure 4). Accordingly, we recently showed that the SH deletion in
the C-85473 backbone limits the virus-induced activation of NLRP3-inflammasome both in vitro and
in vivo, and subsequently reduces inflammation and pathogenicity in HMPV infected mice [34].
Moreover, immunization with ∆SH-C-85473 and ∆G-C-85473 fully protected mice against viral
challenge with rC-85473 (Figure 5, Table 2). Remarkably, the post-challenge antibody response
induced in both vaccinated groups was also effective against a heterologous HMPV B strain (Table 2),
contrary to what was observed for the mock-immunized yet challenged group. Evaluation of the real
cross-protection potential of immunization with ∆SH-C-85473 and ∆G-C-85473 candidates is needed.
Additionally, ∆SH-C-85473-immunized mice showed a distinct pulmonary cytokine/chemokine profile
after viral challenge, with a significant increasing expression of several HMPV-response related markers
compared to the WT and ∆G-C-85473 immunized groups (Figure 6A). Interestingly, a high expression
of IL-10 cytokine [45] and G-CSF chemokine, which were reported as T-cell activators [46], was
concomitant with an enhanced recruitment of immune cells (T CD4+, T CD8+, B cells) in lungs of
∆SH-C-85473-immunized mice at five days post-challenge (Figure 6B). Moreover, such a production of
anti-inflammatory cytokine/chemokine counteracts the observed increased production of TNF-α and
IL-6 pro-inflammatory (Figure 6A).
5. Conclusions
Given the significant clinical burden of HMPV [1,2] and some pitfalls in the development of vaccine
candidates [7,40,47], we considered it important to reexamine the gene deletion-based attenuation
approach [6,27,41]. Our study provides compelling evidence on the so far overlooked variable function
of HMPV G and SH proteins relative to the viral background, the differential effects resulting from their
deletion and the potential implications for the design of LAV candidates. In line with this rationale,
the attenuated and broad protective properties displayed by the ∆SH-C-85473-engineered virus, yet
not inducing enhanced disease markers, in addition to its efficient replication in cell-based system,
make it a promising live-attenuated HMPV vaccine candidate.
6. Patents
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